Emtricitabine/rilpivirine/tenofovir

Emtricitabine/rilpivirine/tenofovir
Emtricitabine/rilpivirine/tenofovir
Combination of
Emtricitabine Nucleoside analog reverse transcriptase inhibitor
Rilpivirine Non-nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil fumarate Nucleoside analog reverse transcriptase inhibitor
Clinical data
Pregnancy cat.  ?
Legal status -only (US)
Routes Oral
Identifiers
ATC code  ?
 YesY(what is this?)  (verify)

Emtricitabine/rilpivirine/tenofovir (trade name Complera, Eviplera) is a fixed dose combination of antiretroviral drugs for the treatment of HIV.[1] The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011 for patients who have not previously been treated for HIV.[2] It is available as a once-a-day single tablet.

References